Total
(n=357; n (%))
Cryptococcal antigen (+)
(n=30; n (%))
Cryptococcal antigen (-)
(n=327; n (%))
P
-value
Sex
Female
164 (46)
17 (56.7)
147 (45.0)
0.218
Male
193 (54)
13 (43.3)
180 (55.0)
Age (years); median (IQR)
38 (31-43)
38 (31-41)
38 (31-43)
0.896
CD4 count (cells/μL); median (IQR)
28 (14-53)
15 (7-23)
32 (14-58)
<0.001
< 50 cells/μL
257 (72)
28 (93.3)
231 (70.6)
<0.008
BMI kg/m
2
; median (IQR)
18.3 (16.6-20.1)
16.7 (14.7-18.5)
18.4 (16.7-20.3)
0.0009
< 16 kg/m
2
72 (20.2)
12 (40.0)
60 (18.6)
0.005
Started on ART
337 (94.4)
28 (93.3)
309 (94.5)
0.791
ART regimen (n=337)
0.808
D4T/3TC/NVP
146 (43.3%)
11 (39.3)
135 (43.7)
D4T/3TC/EFV
174 (51.6%)
16 (57.1)
158 (51.1)
Other
17 (5.0%)
1 (3.6)
16 (5.2)
ART: Antiretroviral Treatment; BMI: Body Mass Index; CM: Cryptococcal Meningitis; D4T: Stavudine; EFV: Efavirenz; IQR: Interquartile Range; NVP: Nevirapine; 3TC: Lamivudine
Table 1:
Baseline characteristics of individuals screened for serum cryptococcal antigen (sCrAg) prior to ART initiation with a CD4 count < 100 cells/μL, Phnom Penh, 2008-2012 (N=357).
Goto home»
